Inferences of actinobacterial metabolites to combat Corona virus

Abstract

The entire globe is reeling under the magnitude of the current corona virus pandemic. This menace has proposed severe health and economic threats for all, thereby challenging our human existence itself. Since its outbreak, it has raised the concern and imperative need of developing novel and effective agents to combat viral diseases and now its variants as well. Despite the sincere and concerted efforts of scientists and pharma giants all over the world, there seems to be no ideal recourse found till date. Natural products are rich sources of novel compounds used in the treatment of infectious and non-infectious diseases. There are reports on natural products from microbes, plants and marine organisms that are active against viral targets. Actinobacteria, the largest phylum under the bacterial kingdom, is known for its secondary metabolite production with diverse bioactive potentials. Nearly 65% of antibiotics used in medicine are contributed by Actinobacteria. Compared to antibacterial and antifungal agents, antiviral compounds from Actinobacteria are less studied. In recent years Actinobacteria from under studied/extreme ecosystems are explored for their antiviral properties. Ivermectin and teicoplanin are examples of Actinobacteria-derived antiviral drugs available for commercial use. This review highlights the importance of actinobacteria as future sources of antiviral drug discovery.